Skip navigation

Signatera Looks Deeper


ESMO Recap



  • Clinical Experience of a Personalized and Tumor-Informed Circulating Tumor DNA Assay for Minimal Residual Disease Detection in Oligometastatic Colorectal Cancer Patients

    Presentation #: 81MO
    Stacey A. Cohen, MD, PhD
    University of Washington, Fred Hutchinson Cancer Research Center, USA
  • Bespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients

    Presentation #: 370P
    Emma Ococks, MS
    MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, United Kingdom
  • Prospective Observational Study Monitoring Circulating Tumor DNA in Resectable Colorectal Cancer Patients Undergoing Radical Surgery: GALAXY Study in CIRCULATE-Japan

    Presentation #: 113TiP
    Hiroki Yukami, MD
    National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

Dive Deeper

ctDNA and MRD Testing | Colorectal Cancer Care Tools for Surveillance
Seeing beyond the limit: Detect residual disease and assess treatment response
A personalized, tumor informed approach to detect molecular residual disease with high sensitivity and specificity

Learn More

Presentations are available for on-demand viewing and download. Sign up here to receive up-to-date information about Signatera.